If You Invested in Microbot Med Inc (MBOT)

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. The company develops, manufactures and distributes the LIBERTY® Endovascular Robotic System, described as the first FDA-cleared, single-use, remotely operated robotic solution for peripheral endovascular procedures, designed for precision, efficiency, safety and provider protection.

Business focus and core technology

Microbot Medical concentrates on the use of robotics in endovascular care. According to the company, the LIBERTY System is a compact robotic device intended for precise vascular navigation during peripheral endovascular procedures. It is single-use and remotely operated, and is designed with the goal of reducing radiation exposure and physical strain for clinicians while supporting accurate tool manipulation inside blood vessels.

The company’s activities include the development, manufacturing and distribution of the LIBERTY System, as well as building the commercial and operational infrastructure needed to support its introduction to hospitals and physicians. Microbot Medical describes itself as a breakthrough medical device and MedTech robotics company, emphasizing its focus on endovascular robotics and medical robotics innovation.

Commercial stage and U.S. market entry

Microbot Medical states that it is a commercial stage company. Following U.S. Food and Drug Administration (FDA) 510(k) clearance for the LIBERTY Endovascular Robotic System, the company announced that LIBERTY is commercially available in the U.S. on a limited basis. This limited market release introduces the system to selected high procedure volume regions where the company reports preliminary demand.

The company has described its commercial plans as targeting an estimated 2.5 million peripheral endovascular procedures performed annually in the U.S. As part of its launch readiness, Microbot Medical reports that it has established an experienced commercial leadership team in key sales and marketing roles, expanded its cross-functional team, and partnered with a U.S.-based third-party logistics provider specializing in the medical device industry to support inventory management and customer fulfillment.

LIBERTY Endovascular Robotic System

Across its public communications, Microbot Medical highlights several characteristics of the LIBERTY Endovascular Robotic System:

• It is described as the first, and in some communications the world’s first, FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures.
• It is designed for precise vascular navigation and for improving efficiency and safety in the interventional suite.
• The company reports clinical data from the ACCESS PVI pivotal trial, presented at a professional society meeting, indicating 100% robotic navigation success, a 92% reduction in radiation exposure and no reported adverse device events in that trial setting.
• The system is intended to support peripheral intervention procedures, with examples in company news including liver tumor embolization, prostate artery embolization and uterine fibroid embolization.

Microbot Medical also reports work on Teleintervention™ collaboration, including simulated vascular navigation across two sites within a health system, and mentions ongoing collaborations with institutions in teleintervention and autonomous robotics related to LIBERTY.

Commercial collaborations and early adoption

According to the company’s announcements, Emory University Hospital, an academic medical center in Atlanta, became the first hospital in the world to adopt the LIBERTY system for patient care. Microbot Medical states that it is collaborating with Emory to establish an Endovascular Robotics Program in interventional radiology. The company has also highlighted its presence at medical conferences, including exhibiting LIBERTY at the Symposium on Clinical Interventional Oncology and planning for a broader launch at the Society of Interventional Radiology conference.

To support commercialization, Microbot Medical reports that it has completed the recruitment of its commercial leadership team and has formed partnerships with third-party manufacturers and logistics organizations. These steps are described as part of building the infrastructure to support the limited market release and anticipated broader market release of LIBERTY.

Intellectual property and global positioning

Microbot Medical emphasizes a strong intellectual property portfolio around the LIBERTY technology. The company reports granted patents in the U.S., Japan, China and Israel, including a first patent in Japan covering the core LIBERTY System technology, such as a compact robotic device for driving and manipulating movement of at least one elongate surgical tool. It also reports a total of 20 patents granted and 52 patent applications pending approval across multiple jurisdictions, and describes its global IP portfolio as creating barriers to entry and enabling it to monetize its technology.

While the company’s commercial focus is described as remaining on the U.S. market, Microbot Medical has stated that it is evaluating other global markets that have historically accepted FDA-cleared devices, and that certain markets, such as Japan, represent strategically important opportunities for the LIBERTY System.

Capital markets and NASDAQ listing

Microbot Medical Inc. trades on the NASDAQ under the ticker symbol MBOT. The company has disclosed multiple capital-raising transactions, including the exercise of outstanding preferred investment options and the issuance of new short-term preferred investment options, with the stated intent to use net proceeds for continued development, commercialization and regulatory activities for the LIBERTY Robotic System, potential acquisitions of complementary assets or products, expansion and development of additional applications derived from its existing IP portfolio, and working capital and general corporate purposes.

The company has also reported being added to the Russell Microcap Index, which it characterizes as reflecting its execution and progress. These disclosures appear in current reports on Form 8-K and related press releases.

Regulatory disclosures and governance

Microbot Medical files current reports on Form 8-K with the U.S. Securities and Exchange Commission (SEC) to disclose material events, including:

• Commercial milestones, such as the limited market release of LIBERTY in the U.S. and the first hospital adoption for patient care.
• Intellectual property developments, such as the granting of patents in new jurisdictions.
• Financing transactions, including exercises of preferred investment options and issuance of new options.
• Certain compensation decisions for executives and non-management directors.

These filings provide investors with official information about the company’s operational, commercial, financial and governance developments related to the LIBERTY Endovascular Robotic System and the broader business.

Position within medical robotics and endovascular care

Within the broader medical device and MedTech landscape, Microbot Medical positions itself specifically in endovascular robotics. Its communications describe the company as driving the future of endovascular care through a single-use, remotely operated robotic platform that is intended to support peripheral endovascular procedures and to address clinician safety and workflow considerations.

The company’s news releases repeatedly associate Microbot Medical with themes such as robotics, MedTech, endovascular robotics, medical robotics and innovation, reflecting its focus on applying robotic technologies to interventional radiology and related specialties.